
Opinion|Videos|March 2, 2026
Future Advancements in PBC Care: Innovations on the Horizon
In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.
Advertisement
Episodes in this series

In the final episode, “Future Advancements in PBC Care: Innovations on the Horizon,” the panelists explore current gaps in care and new treatments that are trying to close those gaps.
Led by the moderator, the panelists examine the following critical questions:
- Looking ahead towards the future of primary biliary cholangitis care, what ongoing trials or emerging treatments do you feel are promising or practice-changing?
- What is one final pearl you would like to share about the management of primary biliary cholangitis and the future ahead?
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
Thank you for watching this Peer Exchange series on PBC. Please subscribe to our newsletter for information on upcoming video series.
Advertisement
Related to this article

End-of-study B-Well data show 91% of patients with chronic hepatitis B who achieved functional cure with bepirovirsen maintained it through Week 96.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Post hoc phase 2 data show survodutide improved MASH and fibrosis endpoints across all weight loss categories, including patients losing less than 5%.

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.
Advertisement
Advertisement
Trending on HCPLive
1
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
2
Cannabis Use Tied to Higher Odds of Stroke, Cardiovascular Disease
3
AHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
4
STREAM: Statin Discontinuation Noninferior in Older Adults Without CVD
5

